• India's Pharma Marketplace
pharma franchise dealspharma franchise dealspharma franchise dealspharma franchise deals
  • Home
  • About us
  • PCD Pharma Franchise
  • Third Party Manufacturing
  • Products
    • Tablet
    • Injection
    • Syrup
    • Drops
    • Capsules
    • Cream
  • Contact

  • Home
  • Tablet
  • Abacavir Sulphate Tablets
Awaiting product image

Abacavir Sulphate Tablets Third Party Manufacturers - WHO GMP Certified

SKU: 1159e5382ae1 Category: Tablet
Send an enquiry
×





    Share
    Description

    10 x 10 (Alu-Alu)

    Abacavir Sulphate Tablets are a key medication used in the treatment of Human Immunodeficiency Virus (HIV) infection. Abacavir, the active ingredient, is classified as a nucleoside reverse transcriptase inhibitor (NRTI). It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of HIV. This action reduces the viral load in the body, helps improve immune function, and delays the progression to AIDS. Abacavir Sulphate Tablets are generally used in combination with other antiretroviral drugs to enhance therapeutic efficacy and minimize resistance development.

    Dosage Forms Available in Market, Packing Types, Top 10 Brands, MRP, Selling Price, MOQ, Margin for Distributorship & Manufacturer

    Abacavir Sulphate Tablets are available in various dosage forms and packaging types. Below is a detailed table showcasing the top 10 brands, their dosage forms, packing types, Maximum Retail Price (MRP), selling price, Minimum Order Quantity (MOQ), and the margin for distributorship and manufacturers.

    Brand Name Dosage Form Packing Type MRP (INR) Selling Price (INR) MOQ (Tablets) Margin for Distributors (%) Margin for Manufacturers (%)
    Ziagen (ViiV Healthcare) 300 mg Bottle of 60 tablets 4500 3600 10,000 20% 15%
    Abamune (Cipla) 600 mg Bottle of 30 tablets 3200 2560 10,000 20% 15%
    Abavir (Hetero) 300 mg Blister pack of 10 tabs 700 560 20,000 20% 15%
    Abacavir Sulphate (Mylan) 600 mg Blister pack of 10 tabs 1100 880 20,000 20% 15%
    Abacip (Ranbaxy) 300 mg Bottle of 60 tablets 4200 3360 10,000 20% 15%
    Abacavir (Sun Pharma) 300 mg Blister pack of 10 tabs 750 600 20,000 20% 15%
    Abacavir (Aurobindo) 600 mg Bottle of 30 tablets 3300 2640 10,000 20% 15%
    Abacavir Sulphate (Lupin) 300 mg Bottle of 60 tablets 4400 3520 10,000 20% 15%
    Abacar (Natco) 600 mg Blister pack of 10 tabs 1200 960 20,000 20% 15%
    Abacavir (Hikma) 300 mg Blister pack of 10 tabs 800 640 20,000 20% 15%

    3. Market Demand with Statistics till 2024

    The demand for Abacavir Sulphate Tablets has been growing steadily, driven by the increasing prevalence of HIV/AIDS and the enhanced awareness and accessibility of antiretroviral therapies. The market for Abacavir Sulphate Tablets was valued at approximately USD 1.2 billion in 2020 and is projected to reach USD 1.8 billion by 2024, growing at a Compound Annual Growth Rate (CAGR) of around 10%.

    Market Growth Statistics:
    • 2018: USD 1.0 billion
    • 2019: USD 1.1 billion
    • 2020: USD 1.2 billion
    • 2021: USD 1.35 billion
    • 2022: USD 1.5 billion
    • 2023: USD 1.65 billion
    • 2024: USD 1.8 billion

    4. How to Use Abacavir Sulphate Tablets for Effective Results

    For optimal effectiveness, Abacavir Sulphate Tablets should be used according to the following guidelines:

    • Dosage: The standard dosage is one 300 mg tablet twice daily or one 600 mg tablet once daily.
    • Combination Therapy: Abacavir Sulphate Tablets are often used in combination with other antiretroviral medications to enhance efficacy.
    • Consistency: Take the medication at the same time each day to maintain consistent drug levels in the bloodstream.
    • Food Intake: These tablets can be taken with or without food.
    • Adherence: It is critical to adhere strictly to the prescribed regimen to prevent the development of drug resistance.

    5. Precautionary Measures to Save from Side Effects

    While Abacavir Sulphate Tablets are effective in managing HIV, they can cause side effects. The following precautionary measures can help mitigate these risks:

    • Hypersensitivity Reaction: Abacavir can cause severe hypersensitivity reactions. Genetic testing (HLA-B*5701 allele) is recommended before starting therapy to identify those at risk.
    • Regular Monitoring: Regular blood tests should be conducted to monitor liver and renal function and overall health.
    • Alcohol Consumption: Patients should avoid excessive alcohol consumption as it can exacerbate liver-related side effects.
    • Adverse Symptoms: Patients should report symptoms such as rash, fever, nausea, vomiting, diarrhea, abdominal pain, or difficulty breathing to their healthcare provider immediately.
    • Drug Interactions: Patients should inform their healthcare provider about all other medications they are taking to avoid potential drug interactions.

    Conclusion: Third Party Manufacturing & PCD Franchise Opportunity

    The manufacturing of Abacavir Sulphate Tablets involves stringent quality control measures to ensure high efficacy and safety standards. Companies engaged in the production of these tablets must comply with Good Manufacturing Practices (GMP) and other regulatory guidelines.

    For businesses and entrepreneurs, the PCD (Propaganda Cum Distribution) franchise model presents an excellent opportunity. By partnering with established pharmaceutical manufacturers, PCD franchise holders can distribute high-quality Abacavir Sulphate Tablets and other antiretroviral drugs, thereby expanding their market reach and addressing the growing demand for effective HIV treatment.

    Third-party manufacturing offers another viable option. Businesses can leverage the capabilities of experienced manufacturers to produce Abacavir Sulphate Tablets under their brand name, focusing on marketing and distribution without needing their manufacturing facility.

    By opting for third-party manufacturing and the PCD franchise model, businesses can contribute to improving healthcare outcomes for HIV patients while building a profitable venture in the pharmaceutical sector.

    FAQs to Enhance the Business Model in PCD Franchise & Third Party Manufacturing of Abacavir Sulphate Tablets

    Q 1.) What is the minimum order quantity (MOQ) for third-party manufacturing of Abacavir Sulphate Tablets?

    Ans 1.) The MOQ for third-party manufacturing varies by manufacturer but typically ranges from 10,000 to 50,000 tablets.

    Q 2.) How can I ensure the quality of Abacavir Sulphate Tablets manufactured by a third party?

    Ans 2.) Ensure the manufacturer complies with GMP standards, and request quality certificates and batch testing reports.

    Q 3.) What are the key benefits of taking a PCD franchise for Abacavir Sulphate Tablets?

    Ans 3.) Benefits include low investment, extensive product portfolio, monopoly rights in a specific territory, and support from the parent company in marketing and distribution.

    Q 4.) How can I obtain the necessary licenses and approvals to distribute Abacavir Sulphate Tablets?

    Ans 4.) Obtain a drug license, GST registration, and other required permits from local health authorities and regulatory bodies.

    Q 5.) What support can I expect from the parent company in a PCD franchise model?

    Ans 5.) Support typically includes marketing materials, product training, promotional strategies, and assistance in regulatory compliance.

    Explore Other Third Party Manufacturing Products - (Category Wise)

    Product Name Compostion
    Product Name Compostion
    Product Name Compostion
    Product Name Compostion
    Product Name Compostion
    No products found
    Product Name Compostion
    Product Name Compostion
    No products found
    Product Name Compostion
    No products found
    Product Name Compostion
    Product Name Compostion
    Copyright 2018 - All Rights Reserved
    Contact Us
    ×